Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.
Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse.
MSGene
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
Dimethyl fumarate attenuates experimental autoimmune neuritis through the nuclear factor erythroid-derived 2-related factor 2/hemoxygenase-1 pathway by altering the balance of M1/M2 macrophages.
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
Brain reserve against physical disability progression over 5 years in multiple sclerosis.
The value of qualitative and quantitative assessment of lesion to cerebral cortex signal ratio on double inversion recovery sequence in the differentiation of demyelinating plaques from non-specific T2 hyperintensities.
Neuroprotective effects of resident microglia following acute brain injury.
Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study.
The Brain as a Target of Inflammatory Processes
[Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis].
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.
Episode 29 with Dr. Monica Carson on MS research funding
Rituximab does not reset defective early B cell tolerance checkpoints.
Microglia across the lifespan: from origin to function in brain development, plasticity and cognition.
Interleukin-1beta promotes repair of the CNS.
Validation of the Brazilian version of the neurological fatigue index for multiple sclerosis.
Relationship between disease-modifying therapy and depression in multiple sclerosis.
Episode 19 with Dr. Samuel Ludwin on treating MS subtypes

Pages